George Heavner
57Patents
18h-index
37Co-inventors
84Inventor score
Filing activity: Jul 1, 1976 → Feb 14, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7250165B2 | Anti-TNF antibodies, compositions, methods and uses | Emerging Cross-Sectional Technologies | 187 | Expired |
| US4289759A | Immunoregulatory diketopiperazine compounds | Human Necessities | 150 | Expired |
| US7521206B2 | Anti-TNF antibodies, compositions, methods and uses | Emerging Cross-Sectional Technologies | 81 | Expired |
| US5618785A | Peptide inhibitors of selectin binding | Human Necessities | 64 | Expired |
| US5710123A | Peptide inhibitors of selectin binding | Human Necessities | 63 | Expired |
| US4331595A | Immunoregulatory diketopiperazine compounds | Human Necessities | 45 | Expired |
| US6111065A | Peptide inhibitors of inflammation mediated by selectins | Human Necessities | 42 | Expired |
| US5753617A | Peptide inhibitors of cellular adhesion | Human Necessities | 42 | Expired |
| US6528487B1 | Peptide inhibitors of inflammation mediated by selectins | Human Necessities | 41 | Expired |
| US7393662B2 | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses | Emerging Cross-Sectional Technologies | 40 | Expired |
| US4505853A | Enzyme-resistant immunomodulatory peptides | Emerging Cross-Sectional Technologies | 40 | Expired |
| US7718176B2 | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses | Emerging Cross-Sectional Technologies | 35 | Active |
| US4547489A | Conformationally restricted thymopentin-like compounds | Emerging Cross-Sectional Technologies | 33 | Expired |
| US4261886A | Peptides having thymopoietin-like activity | Emerging Cross-Sectional Technologies | 32 | Expired |
| US5298490A | Tetra and penta-peptides useful in regulating the immune system | Human Necessities | 26 | Expired |
| US7691378B2 | Anti-TNF antibodies, compositions, methods and uses | Emerging Cross-Sectional Technologies | 23 | Active |
| US7074755B2 | Erythropoietin conjugate compounds with extended half-lives | Human Necessities | 21 | Expired |
| US4629723A | Potent thymopentin analogs | Emerging Cross-Sectional Technologies | 19 | Expired |
| US7163920B2 | Peptide with osteogenic activity | Human Necessities | 17 | Expired |
| US7241733B2 | Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses | Chemistry; Metallurgy | 16 | Expired |
| US4028401A | (Substituted)ureidoacetohydroxamic acids | Emerging Cross-Sectional Technologies | 13 | Expired |
| US4215111A | Peptides having ubiquitin-like activity | Human Necessities | 13 | Expired |
| US4866121A | B cell differentiating peptides and conjugates thereof | Chemistry; Metallurgy | 12 | Expired |
| US9321836B2 | Anti-TNF antibodies, compositions, methods and uses | Emerging Cross-Sectional Technologies | 12 | Active |
| US4397842A | Peptides having thymopoietin-like activity | Emerging Cross-Sectional Technologies | 11 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.